Suchergebnisse - "Shekarkhand, Tala"

PubPharm (8)

1

Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy

enthalten in: Blood advances | 2024

von Hamadeh, I. | Shekarkhand, T. | Rueda, C. | +19

2

CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

enthalten in: Blood advances | 2024

von Firestone, R. | McAvoy, D. | Shekarkhand, T. | +23

3

Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma

enthalten in: Research square | 2024

von Lesokhin, A. | Nath, K. | Shekarkhand, T. | +21

4

Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma

enthalten in: ResearchSquare.com | 2024

von Lesokhin, A. | Nath, K. | Shekarkhand, T. | +21

5

A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

enthalten in: Leukemia & lymphoma | 2022

von Nath, K. | Shekarkhand, T. | Salcedo, M. | +19

6

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Shah, U. | Maclachlan, K. | Derkach, A. | +35

7

Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets

enthalten in: bioRxiv.org | 2022

von Shah, U. | Maclachlan, K. | Derkach, A. | +33

8

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma : The MANHATTAN Nonrandomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Landgren, O. | Hultcrantz, M. | Diamond, B. | +40

1
[1]